Synthesis and preclinical evaluation of [11C]PAQ as a PET imaging tracer for VEGFR-2
- 14 March 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 36 (8), 1283-1295
- https://doi.org/10.1007/s00259-009-1111-3
Abstract
(R,S)-N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-3-piperidinyl)methoxy)-4-quinazolinamine (PAQ) is a tyrosine kinase inhibitor with high affinity for the vascular endothelial growth factor receptor 2 (VEGFR-2), which plays an important role in tumour angiogenesis. The aim of this work was to develop and evaluate in mice the 11C-labelled analogue as an in vivo tracer for VEGFR-2 expression in solid tumours. [11C]PAQ was synthesized by an N-methylation of desmethyl-PAQ using [11C]methyl iodide. The tracer’s pharmacokinetic properties and its distribution in both subcutaneous and intraperitoneal tumour models were evaluated with positron emission tomography (PET). [18F]FDG was used as a reference tracer for tumour growth. PET results were corroborated by ex vivo and in vitro phosphor imaging and immunohistochemical analyses. In vitro assays and PET in healthy animals revealed low tracer metabolism, limited excretion over 60 min and a saturable and irreversible binding. Radiotracer uptake in subcutaneous tumour masses was low, while focal areas of high uptake (up to 8% ID/g) were observed in regions connecting the tumour to the host. Uptake was similarly high but more distributed in tumours growing within the peritoneum. The pattern of radiotracer uptake was generally different from that of the metabolic tracer [18F]FDG and correlated well with variations in VEGFR-2 expression determined ex vivo by immunohistochemical analysis. These results suggest that [11C]PAQ has potential as a noninvasive PET tracer for in vivo imaging of VEGFR-2 expression in angiogenic “hot spots”.Keywords
This publication has 47 references indexed in Scilit:
- Imaging of VEGF Receptor in a Rat Myocardial Infarction Model Using PETJournal of Nuclear Medicine, 2008
- Monitoring of the Biological Response to Murine Hindlimb Ischemia With 64 Cu-Labeled Vascular Endothelial Growth Factor-121 Positron Emission TomographyCirculation, 2008
- Therapeutic antibodies targeting angiomotin inhibit angiogenesis in vivoThe FASEB Journal, 2007
- ZD6474 reverses multidrug resistance by directly inhibiting the function of P-glycoproteinBritish Journal of Cancer, 2007
- In Vivo VEGF Imaging with Radiolabeled Bevacizumab in a Human Ovarian Tumor XenograftJournal of Nuclear Medicine, 2007
- Angiogenesis: an organizing principle for drug discovery?Nature Reviews Drug Discovery, 2007
- New approaches for the synthesis of isotopically labelled guanidine‐derived amino acids and noradrenaline reuptake inhibitorsJournal of Labelled Compounds and Radiopharmaceuticals, 2007
- The biology of VEGF and its receptorsNature Medicine, 2003
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971